Tag: schizophrenia research

Negative symptoms of schizophrenia remain one of the toughest challenges in treatment

These symptoms often include:
🔹 Decreased motivation (avolition)
🔹 Blunted or flat affect
🔹 Reduced emotional range
🔹 Paucity of speech (alogia)

Unlike positive symptoms, negative symptoms respond poorly to antipsychotic medications—even clozapine, our most effective agent for treatment-resistant illness, offers limited relief.

These deficits are often chronic, functionally disabling, and deeply impact quality of life.

Tackling negative symptoms will be the next frontier in improving long-term outcomes in schizophrenia. We need innovative approaches, novel mechanisms, and more research focused on this under-addressed domain.

0

Suicide is a tragically common outcome in schizophrenia

🔹 Up to 50% of patients attempt suicide
🔹 Around 10% die by suicide

The InterSePT trial directly addressed this crisis by comparing clozapine vs olanzapine in high-risk patients—all with recent suicidal ideation or attempts. Notably, only 27% were treatment-resistant.

âś… Clozapine led to a 25% reduction in suicidal behaviors—a game-changer.
đź“Ś This led to FDA approval for clozapine in reducing suicidality in schizophrenia.

Let’s stop thinking of clozapine only as a last resort. Sometimes, it’s exactly what’s needed—not later, but now.

0

New Mechanism, Promising Results: Novel PDE10A Inhibitor for Acute Schizophrenia

A novel PDE10A inhibitor just showed safety and efficacy in a large Phase 2 trial for acute schizophrenia. đź‘Ź

đź“Ś PDE10A inhibitors represent a non-dopaminergic approach—targeting phosphodiesterase 10A to modulate both D1 and D2 pathways indirectly. This could be a game-changer for patients who don’t respond to or can’t tolerate traditional D2 blockers.

🔍 The trial demonstrated:
âś… Significant reduction in PANSS total scores
âś… Favorable side effect profile (no EPS or prolactin elevation)
âś… Oral formulation, once daily

This reinforces the urgent need to diversify our treatment mechanisms beyond dopamine antagonism. As treatment-resistant schizophrenia remains a major challenge, we’ll take all the innovation we can get.

🧠 Stay tuned—PDE10A could join the ranks of TAAR1 agonists and muscarinic agents in reshaping how we treat serious mental illness.

0

Dexmedetomidine for Acute Agitation in Bipolar and Schizophrenia: Worth the Hype?

I recently received a great question about the use of dexmedetomidine for acute agitation. With its recent FDA approval for agitation associated with bipolar disorder and schizophrenia, it’s only natural to wonder: is this the new go-to treatment, or just another overhyped medication?

Let’s start with the obvious. New medications almost always come with a hefty price tag. That cost is only justifiable if they outperform existing options in either efficacy or safety—and in this case, dexmedetomidine falls short on both fronts.

Current data suggest it does not provide superior outcomes when compared to existing, well-established medications like lorazepam, haloperidol, or olanzapine. And it brings along its own baggage: bradycardia, hypotension, and sedation-related complications that can be clinically significant, especially in medically complex patients.

When you combine the high cost with a safety profile that raises some red flags—and no clear advantage in efficacy—it becomes hard to justify widespread use.

For now, I’d place dexmedetomidine in the “hype” category. We already have effective, affordable options with strong track records in managing acute agitation. Until further data prove otherwise, there’s little reason to switch.

0

Substance-Induced Psychosis vs. Primary Psychosis: Treatment, Prognosis, and the Cannabis Connection

Psychosis can emerge from a range of causes, but distinguishing between substance-induced psychosis (SIP) and primary psychotic disorders like schizophrenia is critical for effective treatment and prognosis. While the clinical presentation often overlaps—hallucinations, delusions, disorganized thinking—the underlying etiology, treatment approach, and long-term outcomes can diverge significantly.

Defining the Two

Substance-Induced Psychosis (SIP) occurs when symptoms of psychosis are directly caused by intoxication with or withdrawal from substances such as cannabis, amphetamines, alcohol, hallucinogens, or synthetic cannabinoids (e.g., spice or K2). The psychosis typically emerges during or shortly after substance use and resolves with abstinence.

Primary Psychosis, on the other hand, refers to psychotic disorders that are not directly attributable to substances or medical conditions. This includes schizophrenia, schizoaffective disorder, and brief psychotic disorder, among others.

Treatment: Overlapping Tools, Different Emphasis

1. Acute Management
Both SIP and primary psychosis are often treated with antipsychotic medications during acute episodes. The initial goals are the same: reduce agitation, manage delusions or hallucinations, and ensure safety.

  • Commonly used antipsychotics include risperidone, olanzapine, haloperidol, and quetiapine. In SIP, short-term use is typically sufficient.
  • In cases involving severe agitation or aggression, benzodiazepines (like lorazepam) may be used adjunctively, especially if stimulant intoxication is suspected.

2. Long-Term Strategy

  • SIP: After stabilization, the primary strategy is abstinence from the offending substance and psychosocial support (e.g., CBT, motivational interviewing, relapse prevention).
  • Primary psychosis: Typically requires ongoing antipsychotic treatment, often for life. Psychosocial interventions, supported employment, and cognitive remediation are also central to recovery.

Conversion to Schizophrenia: What’s the Risk?

One of the key concerns with SIP is whether the episode is a harbinger of an underlying primary psychotic disorder.

  • Approximately 20–50% of individuals with substance-induced psychosis later develop a primary psychotic disorder, such as schizophrenia.
  • Amphetamine- and cannabis-induced psychosis carry the highest risk of conversion, particularly when psychosis occurs in adolescence or early adulthood.
  • A meta-analysis by Niemi-Pynttäri et al. (2013) found that 46% of people with SIP later developed schizophrenia-spectrum disorders over a follow-up of 8 years.

Predictors of conversion include:

  • Younger age at first psychotic episode
  • Family history of psychotic illness
  • Persistent psychotic symptoms after substance clearance
  • Poor premorbid functioning

Do Antipsychotics Work in SIP?

Antipsychotics reduce acute psychotic symptoms in SIP, but their long-term utility is less clear.

  • Studies show rapid resolution of psychosis within days to weeks in most SIP cases when abstinence is achieved.
  • Long-term antipsychotic treatment does not reduce the conversion rate to schizophrenia in confirmed SIP, suggesting their role should be time-limited unless ongoing symptoms or risk factors emerge.
  • A 2020 review in Psychological Medicine emphasized that monitoring over the 6–12 months post-episode is essential for risk stratification and avoiding premature chronic medication exposure.

Cannabis: A Powerful Catalyst

Cannabis has become the most studied and most controversial substance linked to psychosis. Here’s what the evidence says:

  • Daily cannabis users are 3–5 times more likely to develop a psychotic disorder compared to non-users, especially with high-THC strains (≥10% THC).
  • A 2019 Lancet Psychiatry study by Di Forti et al. showed that strong cannabis use accounts for 12% of new psychosis cases in Amsterdam, and 30% in London.
  • Adolescents who use cannabis, particularly those with a family history of psychosis, are at dramatically increased risk.

Mechanistically, THC may dysregulate the dopamine system in vulnerable brains, tipping the balance toward psychosis. Cannabidiol (CBD), in contrast, may be protective, but commercial cannabis typically contains very little CBD.

Final Thought: Clinicians must balance vigilance and restraint—treating psychosis aggressively when needed but also avoiding unnecessary chronic antipsychotic exposure in what may be a reversible, substance-driven episode.

0

ARISE Study Phase 3 Results: Understanding Xanomeline’s Setback

What Was the ARISE Study?

The ARISE trial was a Phase 3 clinical study evaluating Cobenfy — a combination of xanomeline (a muscarinic receptor agonist) and trospium chloride (a peripheral anticholinergic) — as an adjunctive treatment for adults with schizophrenia who continued to experience symptoms despite taking an atypical antipsychotic.

What Is a Primary Endpoint, and Why Does It Matter?

In clinical trials, the primary endpoint is the most important outcome researchers are trying to affect — it’s how a drug’s success or failure is officially judged.
In ARISE, the primary endpoint measured the change in symptom severity compared to placebo using a standardized scale for schizophrenia. Meeting this endpoint would have demonstrated clear, statistically significant symptom improvement attributable to Cobenfy.

The Outcome: No Statistically Significant Benefit

According to topline results, Cobenfy did not show a statistically significant improvement compared to placebo when added to atypical antipsychotics. This means the observed difference could have been due to chance and did not meet the pre-set threshold for success.

However, Cobenfy did show a numerical improvement â€” the group receiving the drug combination performed betterthan placebo in symptom reduction, just not to a statistically convincing degree.

Could Anticholinergic Effects Be to Blame?

One possible explanation for this outcome lies in the mechanism of action of both Cobenfy and many commonly used atypical antipsychotics.

  • Xanomeline is designed to activate muscarinic receptors in the brain (specifically M1 and M4), which may help regulate dopamine and reduce psychosis.
  • But many atypical antipsychotics — like olanzapine, clozapine, and quetiapine — also have anticholinergic properties, meaning they block these same receptors.

This sets up a pharmacological tug-of-war: Cobenfy tries to stimulate muscarinic activity, while the background antipsychotic may be dampening it. This conflict could blunt the therapeutic signal, explaining why the benefit didn’t reach statistical significance.

What This Means for the Future

The failure to meet the primary endpoint is a setback, but not the end of the road. The numerical improvements suggest a potential signal, and with refined trial design — perhaps using background medications with lower anticholinergic load — future studies may better reveal Cobenfy’s potential.

Additionally, this trial underscores the importance of considering mechanism compatibility in combination therapies. It’s not just about adding drugs — it’s about how they interact at the receptor level.

Conclusion

While the ARISE study didn’t deliver the result many hoped for, it raised critical questions that will shape future research. A deeper understanding of anticholinergic burden, drug synergy, and precision pharmacology is essential as we continue the search for more effective treatments for schizophrenia.

0

🚨 AI Predicting Schizophrenia & Bipolar Disorder? Not So Fast…

A new study trained an AI model on 24,000+ electronic health records (EHRs) to predict whether a patient would develop schizophrenia or bipolar disorder. The results? 🤔

🔍 The XGBoost machine learning model showed better performance for schizophrenia than bipolar disorder.
đź“Š It achieved an AUC of 0.70 on training data and 0.64 on the test set.
⚠️ But here’s the catch: despite 96.3% specificity, the model’s sensitivity was just 9.3%, meaning it missed the vast majority of cases.

đź’ˇ Bottom Line: AI in psychiatry is promising, but we’re not at the point where a model like this could reliably flag patients at risk. High specificity sounds great—until you realize the trade-off is missing 90%+ of those who actually transition to schizophrenia or bipolar disorder.

Will future AI tools get better at predicting these life-altering conditions? Time (and data) will tell. ⏳

0

🌿 CBD for Psychosis? A Landmark Trial is Underway 🧠

A major new study—the Stratification and Treatment in Early Psychosis (STEP) trial—is set to investigate CBD as a potential treatment for psychosis on a larger scale than ever before. Led by Philip McGuire, MD, professor of psychiatry at Oxford University, STEP will involve 1,000 participants across 30 sites in 10 countries đźŚŤ, making it one of the most ambitious trials of its kind.

🔬 Why it matters:
âś… CBD has shown promise in early studies for psychosis, but large-scale evidence is needed.
âś… STEP will combine three smaller trials to explore effectiveness, biomarkers, and precision treatment approaches.
âś… Nature Medicine named it one of 11 studies that will shape medicine in 2025.

🚀 Could CBD redefine psychosis treatment? The results could change the landscape of psychiatric care. Stay tuned!

0

🚨 Big News for Clozapine Prescribers & Patients!

The FDA has officially ended the Clozapine REMS program—meaning no more mandatory registration, reporting, or ANC submissions to the REMS system! 🙌

What does this mean?
âś… Prescribers â€“ No more REMS hurdles, but ANC monitoring is still recommended.
âś… Pharmacies â€“ No REMS verification needed before dispensing.
âś… Patients â€“ No more REMS-related delays in getting your medication!

This long-awaited change follows input from an FDA advisory committee and aims to reduce unnecessary barrierswhile keeping clozapine use safe and effective.

đź’¬ What are your thoughts on this update? Drop a comment below! 👇

0

🚨 AI Predicting Schizophrenia & Bipolar Disorder? Not So Fast…

A new study trained an AI model on 24,000+ electronic health records (EHRs) to predict whether a patient would develop schizophrenia or bipolar disorder. The results? 🤔

🔍 The XGBoost machine learning model showed better performance for schizophrenia than bipolar disorder.
📊 It achieved an AUC of 0.70 on training data and 0.64 on the test set.
⚠️ But here’s the catch: despite 96.3% specificity, the model’s sensitivity was just 9.3%, meaning it missed the vast majority of cases.

đź’ˇ Bottom Line: AI in psychiatry is promising, but we’re not at the point where a model like this could reliably flag patients at risk. High specificity sounds great—until you realize the trade-off is missing 90%+ of those who actually transition to schizophrenia or bipolar disorder.

Will future AI tools get better at predicting these life-altering conditions? Time (and data) will tell. ⏳

0

Powered by WordPress.com.

Up ↑